Gounder, Mrinal

selected publications

Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. Cancer. 2020 Academic Article GET IT
Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 43
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA oncology. 2020 Academic Article GET IT
Times cited: 130
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. European journal of cancer. 2020 Information Resource GET IT
Times cited: 67
Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Cancer. 2019 Academic Article GET IT
Times cited: 39
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2019 Academic Article GET IT
Times cited: 8
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational new drugs. 2018 Academic Article GET IT
Times cited: 33
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. British journal of cancer. 2018 Academic Article GET IT
Times cited: 4
Reply to E. Younger et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Article GET IT
Times cited: 1
Locally Aggressive Connective Tissue Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Information Resource GET IT
Times cited: 51
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology. 2017 Academic Article GET IT
Times cited: 101
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature medicine. 2017 Academic Article GET IT
Times cited: 2338
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 20
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 12
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 14
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 107
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 129
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma. Sarcoma. 2016 Academic Article GET IT
Times cited: 10
Genomic aberrations frequently alter chromatin regulatory genes in chordoma. Genes, chromosomes & cancer. 2016 Academic Article GET IT
Times cited: 55
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer. 2016 Academic Article GET IT
Times cited: 10
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. The oncologist. 2015 Academic Article GET IT
Times cited: 23
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 17
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. European journal of cancer. 2015 Academic Article GET IT
Times cited: 80
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 12
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. Oncotarget. 2015 Academic Article GET IT
Times cited: 12
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology. 2015 Academic Article GET IT
Times cited: 44
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015 Academic Article GET IT
Times cited: 50
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human pathology. 2014 Academic Article GET IT
Times cited: 240
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 49
Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2014 Academic Article GET IT
Times cited: 2
Reply to M. Voskoboynik et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Article GET IT
Times cited: 1
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 32
Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell death & disease. 2013 Academic Article GET IT
Times cited: 202
High-risk features in radiation-associated breast angiosarcomas. British journal of cancer. 2013 Academic Article GET IT
Times cited: 58
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 359
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer discovery. 2013 Academic Article GET IT
Times cited: 473
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 19
Moving forward one Notch at a time. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Editorial Article GET IT
Times cited: 15
Inclusion of patients with brain metastases in phase I trials: an unmet need. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Article GET IT
Times cited: 11
Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 210
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. The Lancet. Oncology. 2008 Information Resource GET IT
Times cited: 105
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. British journal of haematology. 2007 Academic Article GET IT
Times cited: 67

VIVO Weill Cornell Medical College

Mrinal Gounder Associate Professor of Medicine

Publications

selected publications

Contact

full name

Phone

Publications

selected publications

Contact

full name